INmune Bio receives favorable USPTO patentability opinion for CORDStrom platform

Inmune Bio, Inc.

USPTO, as International Search Authority, issued favorable opinion on all claims of PCT/US25/17028 on April 8, 2025.
Opinion confirms novelty, inventive step, and industrial applicability for CORDStrom pooled hucMSC therapy.
Patent, once granted, would provide IP exclusivity for CORDStrom through at least 2045, subject to extensions.
Company plans to accelerate U.S. national application via Patent Prosecution Highway (PPH) fast-track program.
Follows recent Phase 2 trial data showing CORDStrom reduced pain and itch with early skin integrity signals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.